Image via Wikipedia
A study published this week reinforces the potential value of stem cells in repairing major injuries involving the loss of bone structure.
The study shows that delivering stem cells on a polymer scaffold to treat large areas of missing bone leads to improved bone formation and better mechanical properties compared to treatment with the scaffold alone. This type of therapeutic treatment could be a potential alternative to bone grafting operations.
“Massive bone injuries are among the most challenging problems that orthopedic surgeons face, and they are commonly seen as a result of accidents as well as in soldiers returning
In the first human study of its kind, researchers found that using stem cells to re-grow craniofacial tissues—mainly bone—proved quicker, more effective and less invasive than traditional bone regeneration treatments.
Researchers from the University of Michigan School of Dentistry and the Michigan Center for Oral Health Research partnered with Ann Arbor-based Aastrom Biosciences Inc. in the clinical trial, which involved 24 patients who required jawbone reconstruction after tooth removal.
Patients either received experimental tissue repair cells or traditional guided bone regeneration therapy. The tissue repair cells, called ixmyelocel-T, are under development at Aastrom, which is a U-M spinout company.
Line is first from U-M accepted to the U.S. National Institutes of Health registry, now available for federally-funded research
The University of Michigan’s first human embryonic stem cell line will be placed on the U.S. National Institutes of Health’s registry, making the cells available for federally-funded research. It is the first of the stem cell lines derived at the University of Michigan to be placed on the registry.
The line, known as UM4-6, is a genetically normal line, derived in October 2010 from a cluster of about 30 cells removed from a donated five-day-old embryo roughly the size of the period
Image via Wikipedia
Dr. Robert Johnson, MD, of Neurosurgical Associates of San Antonio, is presenting at the 5th Annual Stem Cell Summit in New York on February 16, 2010. Dr. Johnson will be presenting his most recent data proving the efficacy of point of care adult stem cell therapies in spine surgery. Point of care technology utilizes the patient’s own cells derived from bone marrow to inhibit bone growth in spinal fusion procedures. Dr. Johnson believes promoting cell therapy utilizing the patient’s own cells will change the future landscape of medicine.
“The use of autologous stem cells is revolutionizing
Researchers using stem cells must work to make their treatments safer after a 17 year-old boy with a rare genetic disease in 2001 was cured with an embryonic stem cell transplant in Moscow, but then developed benign brain and spinal tumors four years later. According to ‘Plos Medicine’ magazine, Israeli doctors removed cancer from the boy, the tumors developed due to a stem cell treatment that he received.